Faculty profile

Jolie Ringash

Back to faculty

ProfessorDepartment of Radiation OncologyUniversity of Toronto

Jolie Ringash

Professor

Department of Radiation Oncology

Temerty Faculty of Medicine

University of Toronto

Toronto, Ontario, Canada

Supervision signals

Professors usually supervise graduate students in their department's programs.
43 publications in the last five years, latest in 2026.
Senior (last) author on 4 recent papers, a sign of leading a research group.

These signals come from public records, including federal and provincial funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

175

Publications

8,499

Citations

173

Collaborators

Grants

Publications by year

Counts cover the publications linked to this profile. Citations and the h-index appear when the source records them.

Profiles and links

University Profile

Search on Google Scholar

Search on ResearchGate

iDORCID OpenAlex

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Read how they describe their research on their University of Toronto profile.

Latest papers

Prognostic Factors in Sinonasal Cancers: A Multicenter Pooled Analysis.
The Laryngoscope · 2026
Impact of metastasis-directed therapy for metachronous thoracic metastases following definitive (chemo)radiotherapy in p16-positive head and neck squamous cell carcinoma.
Oral oncology · 2026
ASO Visual Abstract: Development and Validation of EsoTIME, a Prognostication Tool for Resected Esophageal and Gastroesophageal Cancer.
Annals of surgical oncology · 2026

All 175 publications

Latest funding

Optimizing head and Neck Tumour And Symptom Control in Patients Unable to Tolerate Curative (Radio)Therapy: a Phase III trial Comparing Stereotactic Body Radiation Therapy (SBRT) to Standard Palliative Radiation Treatment (ON-TASC Study)
CIHR · 2023 · Co-investigator
$1,602,675
SPECT-CT Guided ELEctive Contralateral Neck Treatment (SELECT) for Patients with Lateralized Oropharyngeal Cancer: A Phase III Randomized Controlled Trial
CIHR · 2020 · Co-investigator
$3,203,435
Canadian Cancer Rehabilitation (CanRehab) Team: Improving the systematic identification, management, and treatment of the adverse effects of cancer.
CIHR · 2019 · Co-investigator
$1,101,364

All 6 grants and awards

From the 150 most recent of 175 publications.

Prognostic Factors in Sinonasal Cancers: A Multicenter Pooled Analysis.

Stefanovic M, Hernando-Calvo A, Castro JB, Huang SH, Su J, O'Sullivan B, Ringash J, Galiana IL, Borbalas AL, Cirauqui BC, Hahn E, Teruel I, de Almeida JR, Querol JM, Witterick IJ, Rubió-Casadevall J, Goldstein DP, Siu LL, Waldron J, Oliva M, Spreafico A

The Laryngoscope20264 citations

DOI: 10.1002/lary.70044 PMID: 40856008

Impact of metastasis-directed therapy for metachronous thoracic metastases following definitive (chemo)radiotherapy in p16-positive head and neck squamous cell carcinoma.

Ly S, Rühle A, Bratman S, Cho J, Hosni A, Hahn E, Kim J, McPartlin A, Ringash J, O'Sullivan B, Tsai CJ, Waldron J, Goldstein D, Sanz-Garcia E, Spreafico A, Su J, Tong L, Weinreb I, Huang SH, Hope A

Oral oncology20261 citations

DOI: 10.1016/j.oraloncology.2026.108006 PMID: 42127862

ASO Visual Abstract: Development and Validation of EsoTIME, a Prognostication Tool for Resected Esophageal and Gastroesophageal Cancer.

Harrison LD, Gupta V, Yuen M, Coburn NG, Pugliese M, Ekuma O, Derksen S, Compton C, Boyes R, Davis L, Decker K, Kidane B, Ringash J, Hsu AT, Mahar A, PRESTO Group (Population Registry of Esophageal and Stomach Tumours in Ontario)

Annals of surgical oncology2026

DOI: 10.1245/s10434-025-18679-7 PMID: 41238983

Development and Validation of EsoTIME, a Prognostication Tool for Resected Esophageal and Gastroesophageal Cancer.

Harrison LD, Gupta V, Yuen M, Coburn NG, Pugliese M, Ekuma O, Derksen S, Compton C, Boyes R, Davis L, Decker K, Kidane B, Ringash J, Hsu AT, Mahar A, Population Registry of Esophageal and Stomach Tumours in Ontario (PRESTO) Group

Annals of surgical oncology2026

DOI: 10.1245/s10434-025-18513-0 PMID: 41139180

Quality of Life in Patients With p16+ Oropharyngeal Cancer Receiving Accelerated Radiation Therapy With Either Cisplatin or Cetuximab in the NRG/RTOG 1016 Randomized Controlled Trial.

Ringash J, Torres-Saavedra PA, Gillison ML, Caudell JJ, Adelstein DJ, Harari PM, Sturgis EM, Basch E, Koyfman SA, Krempl GA, Blakaj DM, Bates JE, Galloway TJ, Jones CU, Beadle BM, Harris J, Le QT, Yom SS, Movsas B

International journal of radiation oncology, biology, physics2026First author

DOI: 10.1016/j.ijrobp.2026.02.242 PMID: 41825810

Prognostic value of baseline EORTC QLQ-C30 scores for overall survival across 46 clinical trials covering 17 cancer types: a validation study.

Lim L, Machingura A, Taye M, Pe M, Coens C, Martinelli F, Alanya A, Antunes S, Tu D, Basch E, Ringash J, Brandberg Y, Groenvold M, Eggermont A, Cardoso F, Van Meerbeeck J, Koller M, Van der Graaf WTA, Taphoorn MJB, Koekkoek JAF, Reijneveld JC, Soffietti R, Velikova G, Bottomley A, Flechtner H, Musoro J, EORTC Quality of Life Group, Brain Tumour Group, Breast Cancer Group, Melanoma Group, Lung Cancer Group, Soft Tissue and Bone Sarcoma Group, Radiation Oncology Group, Lymphoma Group, Gastrointestinal Tract Cancer Group, Head and Neck Cancer Group, Genito-Urinary Cancer Group, Gynaecological Cancer Group

EClinicalMedicine202522 citationsOpen Access

DOI: 10.1016/j.eclinm.2025.103153 PMID: 40201799

Changes in unmet needs after treatment for head and neck cancers - A prospective longitudinal cohort study.

Mathew JM, Busca I, Baskurt Z, Giuliani M, Quartey NK, Jones J, McQuestion M, Papadakos J, Waldron J, Weiss J, Ringash J

Oral oncology20254 citationsSenior author

DOI: 10.1016/j.oraloncology.2025.107250 PMID: 40081185

Outcomes following IMRT alone in head and neck squamous cell carcinoma ordinarily managed with concurrent chemo-radiotherapy.

Barcelona MVN, Waldron J, Sullivan BO, Su J, Bratman SV, Cho JB, Hahn E, Hope AJ, Hosni A, Kim J, McPartlin A, Ringash J, Malik N, Siu LL, Spreafico A, Eng L, Sanz-Garcia E, Yao CMK, de Almeida J, Tong L, Xu W, Tsai CJ, Huang SH

Oral oncology20254 citations

DOI: 10.1016/j.oraloncology.2025.107299 PMID: 40262333

Risk factors and survival impact of severe radiation-related late toxicities in head and neck cancer-a cohort study.

Mathew JM, Ringash J, Su J, Levin W, Bratman S, Cho BCJ, Hahn E, Abdalaty AH, Hope A, Kim J, McPartlin A, O'Sullivan B, Tsai CJ, Waldron J, Spreafico A, Goldstein D, Woodside M, Cruz DJ, Parmelee S, Kwan JYY, Huang SH, Wong P

Lancet regional health. Americas20254 citationsOpen Access

DOI: 10.1016/j.lana.2025.101218 PMID: 40979451

Impact of Surgeon-Radiation Oncology Dyads in Oral Cavity Cancer Outcomes.

Wihlidal J, Esemezie AO, Huang SH, Watson E, Gilbert RW, Waldron J, Gullane PJ, Hope A, Irish JC, O'Sullivan B, Chepeha DB, Kim JJH, Brown D, Cho BCJ, Witterick IJ, Monteiro E, Davies JC, Ringash J, Goldstein DP, Bratman S, Bayley A, de Almeida JR, Chan TCY, Hosni A, Yao CMKL

Annals of surgical oncology20252 citations

DOI: 10.1245/s10434-024-16385-4 PMID: 39467971

Profile data last refreshed on September 29, 2026 from the university directory, publication records and public research funding records.

Something wrong or missing on this profile? Suggest a correction

Jolie Ringash

Research

Latest papers

Latest funding

Prognostic Factors in Sinonasal Cancers: A Multicenter Pooled Analysis.

Impact of metastasis-directed therapy for metachronous thoracic metastases following definitive (chemo)radiotherapy in p16-positive head and neck squamous cell carcinoma.

ASO Visual Abstract: Development and Validation of EsoTIME, a Prognostication Tool for Resected Esophageal and Gastroesophageal Cancer.

Development and Validation of EsoTIME, a Prognostication Tool for Resected Esophageal and Gastroesophageal Cancer.

Quality of Life in Patients With p16+ Oropharyngeal Cancer Receiving Accelerated Radiation Therapy With Either Cisplatin or Cetuximab in the NRG/RTOG 1016 Randomized Controlled Trial.

Prognostic value of baseline EORTC QLQ-C30 scores for overall survival across 46 clinical trials covering 17 cancer types: a validation study.

Changes in unmet needs after treatment for head and neck cancers - A prospective longitudinal cohort study.

Outcomes following IMRT alone in head and neck squamous cell carcinoma ordinarily managed with concurrent chemo-radiotherapy.

Risk factors and survival impact of severe radiation-related late toxicities in head and neck cancer-a cohort study.

Impact of Surgeon-Radiation Oncology Dyads in Oral Cavity Cancer Outcomes.

Optimizing head and Neck Tumour And Symptom Control in Patients Unable to Tolerate Curative (Radio)Therapy: a Phase III trial Comparing Stereotactic Body Radiation Therapy (SBRT) to Standard Palliative Radiation Treatment (ON-TASC Study)

SPECT-CT Guided ELEctive Contralateral Neck Treatment (SELECT) for Patients with Lateralized Oropharyngeal Cancer: A Phase III Randomized Controlled Trial

Canadian Cancer Rehabilitation (CanRehab) Team: Improving the systematic identification, management, and treatment of the adverse effects of cancer.

Development and external validation of a personalized model to predict survival in esophageal cancer patients

Radiation Therapy and Sorafenib for Primary and Metastatic Liver Cancer

Psychometric testing of a new scale measuring medical outcomes of dysphagia (MOD) in adult patients with swallowing disorders secondary to stroke, cervical spine abnormalities and head and neck cancer

Frequent collaborators

John Kim

John Waldron

Brian O'Sullivan

Andrew Hope

Wei Xu

Meredith Giuliani

Scott Bratman

Laura Dawson

John Cho

Andrew Bayley

Ali Hosni

Anna Spreafico

Jonathan Irish

James Brierley

Bernard Cummings

Rebecca Wong

David Goldstein

Ian Witterick

Lillian Siu

Rosemary Martino

Ezra Hahn

Ilan Weinreb

Eugene Yu

Dale Brown

Patrick Gullane

Eric Monteiro

Ralph Gilbert

Eric Bartlett

Ian Poon

Patrik Rogalla

David Roberge

David Payne

Helen MacKay

Savtaj Brar

Jeremy Freeman

Terence Fu

Adam Kwinter

Manish Shah

Thiparom Sananmuang